---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-095450"
form_type: "8-K"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:01:49.036518+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CalciMedica reports Q2 net loss $4.0M; cash $19.1M; positive CARPO topline data

## Summary
- Q2 2024 net loss $4.0M ($0.36/share) vs $3.8M for six months; operating loss $6.5M in Q2.
- Cash, equivalents and short-term investments $19.1M as of June 30, 2024; runway into H2 2025.
- Phase 2b CARPO trial for Auxora in acute pancreatitis met primary objective with statistically significant dose response.
- First patient dosed in Phase 2 KOURAGE trial for severe AKI; topline data expected in 2025.
- Company added to Russell Microcap Index effective July 1, 2024.

## SEC filing metadata
- accession: 0000950170-24-095450
- form_type: 8-K
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000095017024095450/0000950170-24-095450-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000095017024095450/ck0001534133-20240812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-095450
- JSON: https://secwatch.observer/filing/0000950170-24-095450.json
- Plain text: https://secwatch.observer/filing/0000950170-24-095450.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.